These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 30337526)
81. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis. Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790 [TBL] [Abstract][Full Text] [Related]
82. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. Drennan S; Chiodin G; D'Avola A; Tracy I; Johnson PW; Trentin L; Steele AJ; Packham G; Stevenson FK; Forconi F Clin Cancer Res; 2019 Apr; 25(8):2503-2512. PubMed ID: 30373751 [TBL] [Abstract][Full Text] [Related]
83. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649 [TBL] [Abstract][Full Text] [Related]
86. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling. Zhang B; Wang L; Zhang Q; Yan Y; Jiang H; Hu R; Zhou X; Liu X; Feng J; Lin N Mol Oncol; 2019 Apr; 13(4):946-958. PubMed ID: 30663221 [TBL] [Abstract][Full Text] [Related]
87. Development of BTK inhibitors for the treatment of B-cell malignancies. Kim HO Arch Pharm Res; 2019 Feb; 42(2):171-181. PubMed ID: 30706214 [TBL] [Abstract][Full Text] [Related]
88. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know? Galicia-Vázquez G; Aloyz R Crit Rev Oncol Hematol; 2019 Feb; 134():65-70. PubMed ID: 30771875 [TBL] [Abstract][Full Text] [Related]
89. Targeting BTK in CLL: Beyond Ibrutinib. Bond DA; Woyach JA Curr Hematol Malig Rep; 2019 Jun; 14(3):197-205. PubMed ID: 31028669 [TBL] [Abstract][Full Text] [Related]
90. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752 [TBL] [Abstract][Full Text] [Related]
91. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E Oncology; 2019; 97(2):102-111. PubMed ID: 31230047 [TBL] [Abstract][Full Text] [Related]
93. B Cell-Based Cancer Immunotherapy. Wennhold K; Shimabukuro-Vornhagen A; von Bergwelt-Baildon M Transfus Med Hemother; 2019 Feb; 46(1):36-46. PubMed ID: 31244580 [TBL] [Abstract][Full Text] [Related]
94. A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Al-Toubah T; Schell MJ; Cives M; Zhou JM; Soares HP; Strosberg JR Neuroendocrinology; 2020; 110(5):377-383. PubMed ID: 31357193 [TBL] [Abstract][Full Text] [Related]
96. The impact of systemic precision medicine and immunotherapy treatments on brain metastases. Han RH; Dunn GP; Chheda MG; Kim AH Oncotarget; 2019 Nov; 10(62):6739-6753. PubMed ID: 31803366 [TBL] [Abstract][Full Text] [Related]
97. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma. Yue C; Ma H; Zhou Y PeerJ; 2019; 7():e8128. PubMed ID: 31803536 [TBL] [Abstract][Full Text] [Related]
98. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons. Rhodin KE; Rucker AJ; Ready NE; D'Amico TA; Antonia SJ J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1616-1623. PubMed ID: 31836182 [TBL] [Abstract][Full Text] [Related]
99. BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining. Bi KW; Wei XG; Qin XX; Li B Front Oncol; 2020; 10():424. PubMed ID: 32351880 [TBL] [Abstract][Full Text] [Related]
100. A Contrastive-Learning-Based Deep Neural Network for Cancer Subtyping by Integrating Multi-Omics Data. Chai H; Deng W; Wei J; Guan T; He M; Liang Y; Li L Interdiscip Sci; 2024 Sep; ():. PubMed ID: 39230797 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]